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A reversed-phase high-performance liquid chromatographic (HPLC) method was developed and validated for the 
determination of encapsulation efficiency of zidovudine in nanoparticules. The method was carried out in isocratic mode 
using 0.040M sodium acetate: methanol: acetonitrile: glacial acetic acid (880:100:20:2) as mobile phase, a C8 column at 
25ºC and UV detection at 240 nm. The method was linear (r2 ˃ 0.99) over the range of 25.0-150.0 μg/mL, precise (RSD ˂ 
5%), accurate (recovery = 100.5%), robust and selective. The validated HPLC-UV method can be successfully applied to 
determine the rate of zidovudine in nanoparticules. 
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Introduction 
 
About 36 million people are infected with 
the human immunodeficiency virus type-1 
(HIV-1) worldwide (1). The majority of 
infected people live in the developing countries 
with limited treatment resources. Antiretroviral 
(AR) therapy has significantly reduced HIV-1 
disease morbidity and improved life 
expectancy. Treatment failures due to the 
development of resistance and limited global 
access have prevented worldwide utility of AR 
therapy (2,3). Dosing regimens that require 
multiple daily dosing with dietary 
considerations and AR side effects have 
compromised the achievement of long-term 
HIV-1 suppression in infected patients (4). 
Additionally, the use of AR requires a high 
level of commitment from the patient to prevent 
treatment failure due to resistance.  
Zidovudine (Figure 1) was the first 
chemical substance which showed an anti-HIV 
activity, in 1985 (5). Nowadays zidovudine 
continues to be the first choice to the treatment 
of HIV-positive patients (5,6). Zidovudine is a 
class 1 drug according the biopharmaceutical 
classification system (BCS), which is highly 
permeable and highly soluble. And 40% of this 
drug is lost in first pass metabolism (7). 
 
 
 
Figure 1 The structural formule of zidovudine. 
  
Nanoparticles are stable, solid colloidal 
particles consisting of material ranging in size 
from 10 to 1,000 nm. Drugs can be adsorbed on 
the particle surface, entrapped within the 
particle, or dissolved in the particle matrix 
(8,9). Nanoparticles represent an interesting 
carrier system for the transport of antiviral 
drugs to monocyte/macrophage in an attempt to 
Drug Anal Res, 2017; 01, n.2, 1-8 
 
2 
 
reduce the required dose, minimize toxicity and 
side effects, and improve the delivery of 
substances, which have insufficient 
intracellular uptake. Previous studies have 
demonstrated that AR can be fabricated inside 
nanoparticles as a drug delivery system (8,9).  
Zidovudine nanoparticles must be 
analyzed on quality parameters. For 
quantitative determination of zidovudine 
several analytical techniques have been used, 
such as thin layer chromatography (10), 
derivative ultraviolet spectrometry (11), 
capillary electrophoresis (12,13), and high 
performance liquid chromatography (HPLC) 
with ultraviolet detection (14) or with mass 
detection (15,16). A HPLC technique used to 
separate drugs based on hydrophobicity, is a 
good choice to determine the assay because it is 
a cheap, common and selective tool. There are 
official monographs in the United States 
Pharmacopeia for zidovudine determination in 
different pharmaceutical forms (17). However, 
none of these methods was evaluated to analyze 
zidovudine encapsulated in nanoparticles 
which should be simple and fast. 
To assess the encapsulation efficiency 
zidovudine nanoparticles were analyzed by the 
HPLC technique, using an extremely simple 
and fast method that use small sample volume 
requirements and provides detection and 
quantitation of the drug.  
 
Experimental 
 
Materials and reagents 
 
Zidovudine reference standard was 
purchased from Farmacopeia Brasileira 
(Brazil) (99.4% of purity), Zidovudine related 
compound C was purchased from USP (USA) 
(MW 126.12).  Polycaprolactone (MW 
~14,000) was purchased from Sigma Aldrich 
(Germany). Isopropyl myristate and sorbitan 
monooleate was obtained from Sigma Aldrich 
(Germany). Polysorbate 80 was purchased from 
MercK (Germany). Ultrapure water was 
obtained from a Milli-Q® apparatus (Millipore, 
USA).  The others reagents used were HPLC or 
analytical grade.  
 
Instrumentation and analytical conditions 
The HPLC analysis were carried out on a 
Merck Hitachi LaChrom Elite chromatograph 
(Germany) which included a quaternary pump, 
autosampler, column oven and diode array 
detector (DAD). A Lichrocart® column (125 x 
4.0 mm i.d.; 5 μm particle size) from Merck 
(Germany) was used and maintained at 25 ºC. 
The injection volume was 10 μL and detection 
was performed at 240 nm. The mobile phase 
comprised of 0.040 M sodium acetate: 
methanol: acetonitrile: glacial acetic acid 
(880:100:20:2) was used at the flow rate of 1.0 
mL/min. Elma ultrasonic water bath 
(Germany), and Millipore filtration (USA) 
assembly were used in this study.  
 
Preparation of the zidovudine loaded 
nanoparticles 
 
The zidovudine loaded nanoparticles were 
prepared by the nanoprecipitation method, 
which involved mixing an organic phase in an 
aqueous phase (18). The required amounts of 
polymer and drug were dissolved in acetone 
with sorbitan monooleate and isopropyl 
myristate. The organic phase was gradually 
added to the aqueous phase containing 
polysorbate 80 using a small funnel under 
stirring. After, acetone was removed under low 
pressure through a rotary evaporator. 
 
Preparation of solutions 
 
Zidovudine standard solutions, Zidovudine 
related compound C solution, blank sample and 
blank matrix spiked with zidovudine were 
prepared. All the standard solutions were 
filtered through a 0.45 µm filter (Sartorius, 
Germany). The concentration of zidovudine in 
each solution prepared is defined on the 
validation parameter description.  
 
Zidovudine standard solutions  
 
Zidovudine standard solutions at the 
concentrations of 75, 100 and 125 μg/mL were 
prepared by weighing appropriate amount of 
zidovudine reference standard into a 25 mL 
volumetric flask and dissolving it in 18mL 
water using an ultrasonic water bath. Water was 
added to complete the flask volume. The 
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obtained solution was filtered using a 0.45 µm 
filter and 10 mL of filtrated was transferred to a 
100 mL volumetric flask. Water was added to 
complete the flask volume. (n = 3 for each 
level). 
 
Zidovudine related compound C solution 
 
Zidovudine related compound C solution at 
a concentration of 2.0 μg/mL was prepared by 
weighing appropriate amount of zidovudine 
related compound C into a 25 mL volumetric 
flask and dissolving it in 18 mL water using an 
ultrasonic water bath. Water was added to 
complete the flask volume. The obtained 
solution was filtered in 0.45 µm filter and 10 
mL of filtrated was transferred to a volumetric 
flask (100 mL). Water was added to complete 
the flask volume. (n = 3). 
 
Blank matrix 
 
Nanoparticles without drug were prepared 
using the same method described in 
“Preparation of the zidovudine loaded 
nanoparticles” and served as blank matrix. 
 
Blank matrixes spiked with zidovudine 
 
The blank matrix spiked with zidovudine 
reference standard solutions at the 
concentrations of 75, 100 and 125 μg/mL were 
prepared. An appropriate weight of blank 
matrix was transferred to a volumetric flask (25 
mL) containing an appropriate weight of 
zidovudine reference standard. Water (18mL) 
was added to dissolve using an ultrasonic water 
bath. The obtained solution was filtered in a 
0.45 µm filter and 10 mL of filtrated was 
transferred to a volumetric flask (100 mL). 
Water was added to complete the flask volume 
(n = 3 for each level). 
 
Method validation 
 
The method was validated for specificity, 
linearity, precision (repeatability and 
intermediated precision), limits of quantitation 
and detection, accuracy and robustness in 
accordance with standard procedure (19). 
 
Specificity 
 
Specificity was evaluated by comparing the 
following chromatographic peaks: zidovudine 
reference standard at the concentration of 100 
μg/mL, zidovudine related compound C at the 
concentration of 2 μg/mL, mobile phase, 
diluent and blank matrix spiked with 
zidovudine reference standard (100 μg/mL).  
To achieve the method specificity, no peak, 
with the same retention time of zidovudine, was 
allowed. Additionally, spectral purity of 
zidovudine chromatographic peak was 
evaluated through UV spectra recorded by 
diode array detector (DAD). 
 
Stability of solution 
 
The stability of the solution of zidovudine 
was evaluated by analyzing the zidovudine 
standard solution at the concentration of 100 
μg/mL at the moment of the preparation and 
after 24 hours at refrigerator (2 to 8ºC) and 
these areas of peaks were compared.  
 
Linearity 
 
The standard calibration curves were 
obtained from five zidovudine reference 
standard solutions, at the concentrations of 25, 
50, 75, 100, 125 and 150 μg/mL. For each 
standard solution three independent replicates 
were evaluated. These assays were performed 
on two different days. The calibration curves 
obtained were assessed through residue 
analysis (outlier’s test, normality, and 
homoscedascity and residue independence) and 
linear regression analysis was done by ordinal 
least squares method (20). 
 
Limit of detection (LOD) and limit of 
quantitation (LOQ)  
 
The method sensitivity was evaluated by 
determination of the lower quantitation limit 
(LOQ) and the detection limit (LOD). The LOD 
and LOQ were determined based on the signal 
to noise method and blank matrix analysis. The 
LOQ was defined as the lowest zidovudine 
concentration that could be determined with 
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adequate precision and accuracy, whereas the 
LOD was defined as the lowest zidovudine 
concentration that could be detected but not 
quantified under the stated experimental 
conditions (21,22). The blank matrix solutions 
were prepared in triplicate by two analists on 
two different days (n = 12). 
The LOQ and LOD were calculated through 
equations 1 and 2, respectively: 
LOQ = 10 σ/b (Equation 1)  
LOD = 3 σ/b (Equation 2) 
where, σ is the standard deviation of the 
response and b is the slope of the calibration 
curve. 
 
Precision 
 
The intra-day precision (repeatability) was 
evaluated through analysis of the blank samples 
spiked with known amount of zidovudine 
performing 75, 100, and 125 μg/mL of the drug 
on the same day (n = 6 for each concentration). 
Likewise, the inter-day precision (intermediate 
precision) was evaluated through the same 
sample preparation. However, they were 
assessed on two consecutive days (n = 12 for 
each concentration). The precision was 
expressed as relative standard deviation (RSD) 
through the Analysis of the Variance 
(ANOVA).  
 
Accuracy 
 
The zidovudine standard solutions at the 
concentrations of 75, 100, and    125 μg/mL 
were prepared and analyzed. The solutions 
were prepared in triplicate by two analists (n = 
18).  Moreover, blank samples spiked with 
known amount of zidovudine performing 75, 
100, and 125 μg/mL of the drug were also 
prepared and analyzed. The blank samples 
spiked were prepared in triplicate by two 
analists (n = 12). The percent recovery of added 
zidovudine was calculated comparing 
responses of the blank samples with the 
responses of the reference standard zidovudine 
solutions at the same concentration levels.  
 
Robustness 
 
The method proposed by Youden e Steiner 
was carried out to evaluate the robustness (15). 
Seven analytical parameters were selected and 
investigated at two limits of variation relative to 
the nominal value. The upper limits were 
indicated by capital letters and the lower limits 
were indicated by lowercase letters in Table 1. 
Eight chromatographic runs were performed 
following the experimental design of Youden 
and Steiner (Table 1) in order to determine the 
influence of each analytical parameter in the 
final result. 
 
Table 1 Parameters, variation and factorial combination for robustness test 
studies. 
 
Analytical 
parameter 
Value (X/x) 
Factorial combination 
1 2 3 4 5 6 7 8 
Column  A 
C18  
a 
C8  A A A A a a a a 
Wavelength 
(nm) 
B 
238 
b 
242 B B b b B B b b 
Mobile phase 
flow rate 
(mL/min) 
C 
0.8 
c 
1.2 C c C c C c C c 
Proportion of 
the mobile 
phase (0.040 M 
sodium acetate/ 
methanol/ 
acetonitrile/ 
glacial acetic 
acid) 
D 
870:105:2:25 
d 
890:95:2:15 D D d d d d D D 
Injection 
volume (µL) 
E 
8 
e 
12 E e E e e E e E 
Temperature of 
sample 
compartment 
(oC) 
F 
23 
f 
27 F f f F F f f F 
Filter unit G 
cellulose 
g 
PVDF* G g g G g G G g 
Results s t u v w x y z 
*PVDF – Polyvinylidene fluoride 
The zidovudine standard solution at the 
concentration of 100 μg/mL and the blank 
sample spiked with zidovudine at the 
concentration of 100 μg/mL were injected three 
times for each combination. Then, the recovery 
of the spiked zidovudine was calculated. 
The results of each experiment were 
represented by letters ranging from s to z (Table 
1). To estimate the effect of each variation on 
the final result, the difference between the mean 
of the four values corresponding to the capital 
letters (upper limits) and the mean of the four 
values corresponding to the lowercase letters 
(lower limits) was calculated (23). Thus, to 
evaluate the influence, for example, on 
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wavelength in the final result of the analysis, 
Equation 3 was used as given below: 
 
Effect G/g = 4
)(
4
)( zwutyxvs 


 
(Equation 3) 
 
The effect of the analytical parameter was 
considered to be significant if the value of the 
difference was greater than  2S , where, S is 
the standard deviation of the eight results (24). 
 
Application of the validated HPLC-UV 
method for determination of Encapsulation 
efficiency of nanoparticles  
 
Polycaprolactone nanoparticles (600 µL) 
were dissolved in 3 mL of acetonitrile and 
transferred to a volumetric flask (10 mL) (n = 
3). Water was added to complete the flask 
volume. In ultra centrifugal filter units 2 mL of 
polycaprolactone nanoparticles were added and 
centrifuged at 9,000 rpm for 30 minutes. 
Thereafter, 600 µL of the filtrated were 
transferred to a volumetric flask (10 mL) (n=3). 
Water was added to complete the flask volume. 
The amount of zidovudine in both cases was 
determined by the validated high performance 
liquid chromatographic method described 
before. The percentage of zidovudine loaded in 
nanocapsules was calculated by the equation 4:  
(T zidovudine – F zidovudine) x 100 = % 
zidovudine loaded (Equation 4) 
where “T zidovudine” is the concentration of 
total zidovudine and “F zidovudine” is the 
concentration of free zidovudine. 
 
Results and Discussion 
 
Optimization of the chromatographic 
conditions 
 
In this study, an HPLC-UV method was 
optimized and validated for determination of 
zidovudine encapsulated in polycaprolactone 
nanoparticles.  
The optimal absorption wavelength for 
zidovudine detection was chosen based on the 
higher detector response for this drug. 
Therefore, the absorption wavelength for 
detection was set on 240 nm. 
Different proportions of 0.040 M sodium 
acetate: methanol: acetonitrile: glacial acetic 
acid were tested in order to define the 
appropriate mobile phase. The selected mobile 
phase proportion was consisted of a solution 
0.040 M sodium acetate: methanol: acetonitrile: 
glacial acetic acid (880:100:20:2). It was 
observed that increasing the amount of 
acetonitrile in mobile phase the zidovudine 
retention time was reduced due to more affinity 
between the drug and the mobile phase.  
 
Method validation 
 
The specificity of the method was 
investigated and it was observed that 
zidovudine and zidovudine related compound C 
eluted approximately at 12 and 2 minutes 
respectively (Figure 2a and 2b). There was no 
peak on the same retention times of zidovudine 
and zidovudine related compound C during the 
analysis of blank sample (Figure 2c). The 
chromatographic peak of zidovudine was 
completely resolved and none of substances 
from mobile phase or diluent presented the 
same zidovudine retention time of zidovudine. 
Additionally, peak purity higher than 99.0% 
was obtained for the drug in the chromatograms 
of zidovudine spiked in blank sample, 
indicating that other components did not 
coelute with the drug peak. According to 
obtained results, the method showed specificity 
for zidovudine in the presence of the 
polycaprolactone nanoparticles. 
The stability of the solution of zidovudine 
was evaluated by analyzing the area of peaks of 
zidovudine standard solution at the 
concentration of 100 μg/mL at the moment of 
the preparation and after 24 hours under 
refrigeration (2 to 8ºC). This difference of teor 
was 0.82% which showed that zidovudine 
solution to be continued stable after 24 hours 
after of the preparation under refrigeration. 
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Figure 2 (A) Chromatogram of zidovudine at the concentration of  100 µg/mL. 
(B) Chromatogram of Zidovudine related compound C at the concentration of 2.0 
μg/mL. (C) Chromatogram of Blank matrix. Chromatographic conditions: C8 
column 125 mm × 4.0 mm at 25ºC; 0.040 M sodium acetate: methanol: 
acetonitrile: glacial acetic acid (880:100:20:2); 1 mL/min of flow rate; wavelength 
of 240 nm. 
 
A calibration curve relating concentration 
of the drug to area of peaks was plotted and the 
obtained data were subjected to linear 
regression analysis by ordinal least square 
method. The calibration curve was linear over 
the range of 25 μg/mL to 150 μg/mL. The 
linearity could be defined by the following 
equation “y = 30000x – 9172.2”, where y and x 
are the area and the concentration (μg/mL), 
respectively. The significance of the calibration 
curve intercept was tested and this parameter 
was not statistically significant (p > 0.05), 
which can be considered, consequently, that the 
curve passes through the origin (25). The 
correlation coefficient (r) was higher than 0.99, 
showing highly significant correlation between 
concentration and peak area. The determination 
coefficient (R2) of the calibration curve was 
0.9999, implying that 99.99% of total variance 
of the peak areas was explained by the varying 
zidovudine concentration. Finally, the linear 
model proved to be adequate since the residues 
followed a normal distribution pattern and were 
independent, the homoscedasticity could be 
observed and the lack of fit was not significant. 
The LOD was 0.9156 μg/mL and this 
concentration displayed a signal-to-noise ratio 
of 3:1. The LOQ was 2.535 μg/mL and this 
concentration displayed a signal-to-noise ratio 
of 10:1. 
The repeatability (intra-day precision) and 
intermediated precision (inter-day precision) 
were expressed as the relative standard 
deviation (RSD) of a series of measures of 
different concentrations of zidovudine 
incorporated into blank solutions. The data 
obtained for precision were summarized in 
Table 2. The RSD values were lower than 5% 
for all levels of concentrations tested, thus 
indicating appropriate intra and inter-day 
precision (26). 
 
Table 2 Mean content of zidovudine in the intra-day and inter-day precision. 
 
Zidovudine 
concentration 
(µg/mL) 
Mean 
content 
Intra-day 
precision 
Inter-day  
precision 
RSD RSD 
75 101.66 0.25 0.33 
100 101.16 0.50 0.60 
125 100.50 1.01 1.19 
 
The accuracy of the HPLC-UV method was 
expressed as the percent of recovery of 
zidovudine spiked in the blank sample. The 
recovery ranged from 101.16% to 101.66%, as 
demonstrated on Table 3. All the recovery 
values were between 80.0% and 110.0% of the 
theoretical concentration, confirming the 
accuracy of the proposed method. 
 
 
Table 3 Percent recovery of zidovudine spiked in blank matrix. 
 
Zidovudine 
concentration (µg/mL) Percent recovery RSD 
75 101.66 0.32 
100 101.16 0.59 
125 100.50 1.16 
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The results obtained on the robustness test 
are shown in Table 4. The HPLC-UV method 
appears to be robust regarding all the variables 
analyzed, as the difference between results 
obtained in differents conditions were lower 
than the critical value for all analytical 
parameters studied. During the assays, the 
zidovudine retention time was not significantly 
changed and peak symmetry was maintained. 
However, it could be noted that the column and 
mobile phase proportion were the factors that 
had more influence on method performance. 
Thus, these analytical parameters should be 
carefully controlled.  
 
Table 4a Effects of the analytical parameters in the percent of recovery of 
zidovudine. 
 
Analytical 
parameter Recovery of zidovudine (%) Effect X – x 
 
Column 
A 105.55 
4.40 
a 101.15 
Wavelength (nm) 
B 103.68 0.64 
b 103.03 
Mobile phase flow 
rate (mL/min) 
C 
103.43 0.16 
c 
103.28 
Proportion of the 
mobile phase 
(0.040 M sodium 
acetate/ methanol/ 
acetonitrile/ glacial 
acetic acid) 
D 
102.98 
-0.75 
d 
103.73 
Injection volume 
(µL) 
E 103.17 -0.36 
e 103.53 
Temperature of 
sample 
compartment (oC) 
F 
103.26 
-0.19 
f 
103.45 
Filter unit 
G 103.50 0.28 
g 103.21 
 
Application of the validated HPLC-UV 
method for determination of zidovudine 
encapsulated in nanoparticles  
 
The zidovudine standard solution and the 
zidovudine nanoparticles samples were 
prepared, analyzed and quantified by applying 
the validated HPLC-UV method. The 
concentration of free zidovudine and total 
zidovudine were obtained and the percentage of 
encapsulated zidovudine was determinated. 
The encapsulated zidovudine was equal to 
58.23% (58.23 µg/mL) (n = 5). The relative 
standard deviation for five sample replicates 
was 3.4%.  
 
Conclusions 
 
An HPLC-UV method was developed for 
determining the encapsulation efficiency of 
zidovudine in nanoparticles. This 
chromatographic method was considered 
simple and rapid, since the preparation of the 
samples did not involve complex and prolonged 
processes. Furthermore, the HPLC-UV method 
was validated in terms of selectivity, stability, 
linearity, limits of quantitation and detection, 
precision, accuracy and robustness. Finally, it 
provided unequivocal determination of the 
amount of zidovudine in nanoparticule 
formulation which may be applied to stability 
or quality control.  
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